Imaging hypoxia in head and neck cancer for personalized treatment
Official title: Novel Hypoxia Imaging for Head and Neck Cancer: Imaging Phenotype for Personalized Treatment
Run by University of Utah · NCT06108089 · Data updated 2026-11-12
This study is testing a new way to use MRI scans to find low-oxygen areas in head and neck cancer patients to help create personalized treatment plans that could improve their response to therapy.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 20 (estimated) |
| Sponsor | University of Utah Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Salt Lake City, Utah) |
| Status | Recruiting |
| Started | June 28, 2024 |
| Main results expected | December 1, 2027 |
| Study ends | December 1, 2027 |
| Registry record updated | August 5, 2026 |
| Trial ID | NCT06108089 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include newly diagnosed patients with head and neck squamous cell carcinoma scheduled for chemoradiotherapy or surgery.
✕Probably not a fit
Patients with prior treatment for head and neck cancer or those with certain medical conditions, such as uncontrolled diabetes or abnormal kidney function, may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to identify hypoxic features in patients with head and neck cancer using multiparametric hypoxia MRI. By correlating these imaging results with treatment responses assessed through FDG-PET scans, the study seeks to develop a hypoxia phenotype that can inform personalized treatment plans. The research will gather pilot data to measure the distribution of hypoxia MR parameters and their association with outcomes following chemoradiotherapy. Ultimately, the goal is to enhance treatment planning and predict responses to therapy in newly diagnosed patients.
Why it matters
Potential benefit: If successful, this approach could lead to more personalized and effective treatment strategies for patients with head and neck cancer.
How similar studies have gone: While the approach of using hypoxia imaging in cancer treatment is being explored, this specific methodology is novel and has not been extensively tested in prior studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Newly diagnosed HNSCC (head and neck squamous cell carcinoma) by biopsy or fine needle aspiration originating from the oral cavity, larynx, hypopharynx, nasopharynx, and oropharynx * Patients are scheduled to undergo chemoradiotherapy or surgery * Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines. Exclusion Criteria: * Pregnant patients * Patients with claustrophobia * Patients with pacemaker, spinal stimulator, or cochlear implant that are not MR compatible or any other metallic objects in the body * Patients who had been treated for HNC, either surgery, radiation therapy, or chemotherapy * Patients with thyroid, skin, sinonasal, and salivary gland cancer. * Abnormal kidney function defined as estimated glomerular filtration rate (eGRF) \< 30 mL/min/1.73 m2 * Patients with uncontrolled diabetes * Patients who obtained outside FDG-PET/CT prior to initial treatment
Where it's running
-
University of Utah
Salt Lake City, Utah, United States Recruiting
Study contacts
- Principal investigator: Yoshimi Anzai, M.D. — University of Utah
- Study coordinator: Olivia Pratt
- Email: u0447662@utah.edu
- Phone: (801)585-6142
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Adaptive radiotherapy using FMISO for head and neck cancer
This study is testing if using special imaging to find hard-to-treat areas in head and neck cancer can help doctors give higher doses of radiation where it's needed most, along with chemotherapy, to improve patient outcomes.
-
Phenotype-based Pain Guidance for Head and Neck Cancer-Related Pain (pilot)
This pilot test sees if tailoring pain treatment to a patient’s pain type can reduce head and neck cancer pain in adults who haven’t started cancer treatment yet.
-
Airway ultrasound in head and neck cancer patients
This observational study tests whether neck ultrasound measurements of the airway match CT measurements in adults with maxillofacial cancer undergoing surgery with anesthesia.
-
Safe use of metformin and naproxen to help prevent cancer in people with Fanconi anemia
This study tests whether metformin and naproxen can lower the chance of cancer developing in adults with Fanconi anemia.
-
Iparomlimab and Tuvonralimab With Cetuximab Before Surgery in Resectable Oral Cancer
In this phase 2 study, patients with locally advanced, resectable oral squamous cell carcinoma will receive a combination of iparomlimab, tuvonralimab, and cetuximab before surgery to see if the treatment is safe and can shrink tumors.
-
SumMET: Targeted radioligand therapy for c-MET–positive solid tumors
This first‑in‑human study tests the safety and potential effectiveness of a radioligand therapy called [225Ac]Ac-FL-261 in adults with advanced or metastatic solid tumors that overexpress c-MET.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.